Detailed Quote:IPIX INNOVATION PHARMACEUTICALS IN
Post# of 72440
INNOVATION PHARMACEUTICALS INC
0.187Up 0.057 (43.85 %)AS OF 3:59:45PM ET 11/02/2018
Last Trade 0.187
Trade Time 3:59:45pm ET
Change 0.057
% Change 43.85%
Bid 0.1755
Bid Size 5000
Ask 0.187
Ask Size 5000
Open 0.13
Day High 0.189 ** .061c *liquidity*
Day Low 0.128
Previous Close
11/01/2018 0.13
52-Week High
12/06/2017 1.17
52-Week Low
10/19/2018 0.12
Price Performance (Last 52 Weeks)
11/01/2018 -82.55%
Volume 1,372,537
Volume (10 day Average) 841,159
Volume (90 day Average) 421,961
last grab B/A .. may not align with Fido's above
NITE 0.1755 5,000 15:58
CSTI 0.175 5,000 15:56
ETRF 0.175 5,000 15:59
CDEL 0.15 37,230 15:59
VERT 0.125 5,000 10:14
LAFC 0.1103 5,000 10/19
VNDM 0.102 5,000 11/01
STXG 0.1012 5,000 09/28
PUMA 0.10 5,000 08:10
MAXM 0.0001 10,000 07:35
CANT 0.0001 10,000 15:46
DBOX U 0 10/15
INTL U 0 10/24
OTCX U 0 08:15
CDEL 0.187 9,000 15:59
NITE 0.187 5,000 15:57
CSTI 0.188 10,000 15:57
ETRF 0.189 10,000 15:56
VNDM 0.23 2,500 11/01
LAFC 0.35 2,500 10/02
PUMA 0.35 2,500 08:10
CANT 0.36 5,000 11:07
VERT 0.36 2,500 10:13
STXG 2.00 100 >year
MAXM 8.00 100 07:35
DBOX U 0 10/15
INTL U 0 10/24
OTCX U 0 08:15
email in @ 7:30AM
Innovation Pharmaceuticals Submits End of Phase 2 "Briefing Package" to FDA.
Fri, Nov 2, 2018 7:30 am
Dear Innovation Pharmaceuticals Shareholders,
Earlier this week, the company submitted the “briefing package” for our scheduled End-of-Phase 2 meeting to be held later this quarter with the FDA. This is an exciting milestone in the development of oral rinse Brilacidin for the treatment of Oral Mucositis.
A successful FDA meeting would be transformative for our company, opening up enormous potential for our shareholders and, more importantly, for patients who need such a treatment.
I wish to remind shareholders of the results achieved in the Phase 2 study with Brilacidin. In Head and Neck Cancer patients receiving cisplatin administered in a higher concentration (80-100 mg/m2), approximately every 21 days, oral rinse Brilacidin’s results were as follows:
In the Modified Intention-to-Treat population, 71.4% of patients receiving placebo developed severe Oral Mucositis, compared to 25.0% of patients receiving Brilacidin [mITT Population] (p=0.048).
In the Per Protocol population, 72.7% of patients receiving placebo developed severe Oral Mucositis, compared to 14.3% of patients receiving Brilacidin [PP Population] (p=0.025).
The stark difference between how our drug performed against placebo will be a focus of our FDA meeting and provides us with a high-degree of confidence in the treatment potential and commercial value of our asset. As we have shared previously, our research shows there is a significant market opportunity for treating Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, as there currently is no FDA-approved drug. Of course, there are no assurances stated or implied regarding successfully developing a drug, but if we are successful, we believe that earnings from a new, easy-to-use OM drug could be many multiples of our present market cap. This keeps us driving forward in executing on our business model and building shareholder value.
In our next corporate filing (10q), we will be updating shareholders on other ongoing business and clinical development priorities.
11.2.18 .. trades .. markage @ 29.30%
15:59:45 0.187 1000 OTO
15:59:25 0.187 11580 OTO
15:59:20 0.18125 3420 OTO
15:59:14 0.176 5000 OTO
15:59:14 0.18 16580 OTO
15:59:03 0.187 5000 OTO
15:59:00 0.187 2500 OTO
15:59:00 0.187 3000 OTO
15:58:11 0.18 600 OTO
15:58:09 0.181 400 OTO
15:58:09 0.181 5000 OTO
15:57:49 0.18 5500 OTO
15:57:14 0.187 1000 OTO
15:57:09 0.18 10000 OTO
15:56:12 0.187 5000 OTO
15:56:11 0.189 10000 OTO
15:56:03 0.187 10000 OTO
15:53:37 0.187 21500 OTO
15:53:34 0.186 28500 OTO
15:53:02 0.186 500 OTO
15:52:49 0.18 5000 OTO
15:51:49 0.185 1000 OTO
15:49:54 0.187 1400 OTO
15:49:41 0.187 8600 OTO
15:49:33 0.18 5000 OTO
15:49:11 0.18 1000 OTO
15:47:30 0.18 11000 OTO
15:47:17 0.18 2700 OTO
15:45:53 0.18 2285 OTO
15:45:52 0.18 5000 OTO
15:45:39 0.18 7715 OTO
15:44:59 0.18 5500 OTO
15:43:57 0.18 13650 OTO
15:43:52 0.18 3000 OTO
15:43:13 0.18 950 OTO
15:42:48 0.18 4000 OTO
15:42:48 0.175 7350 OTO
15:39:38 0.175 800 OTO
15:38:13 0.175 50 OTO
15:38:12 0.175 10000 OTO
15:37:38 0.175 7600 OTO
15:37:38 0.175 50 OTO
15:29:38 0.18 10000 OTO
15:24:17 0.18 4835 OTO
15:17:55 0.18 1328 OTO
15:17:47 0.175 8672 OTO
15:15:37 0.175 1328 OTO
15:15:00 0.175 10000 OTO
15:14:53 0.17384 100 OTO
15:14:17 0.175 5000 OTO
15:14:12 0.1694 5000 OTO
15:13:52 0.1694 5000 OTO
15:08:48 0.1694 7000 OTO
15:08:47 0.1694 5000 OTO
15:06:28 0.1694 3000 OTO
15:06:24 0.165 7000 OTO
15:04:49 0.1694 5000 OTO
15:04:38 0.1694 2000 OTO
15:02:48 0.16846 5000 OTO
14:50:10 0.174 600 OTO
14:50:07 0.17 5000 OTO
14:49:42 0.1675 4400 OTO
14:49:25 0.17 2500 OTO
14:47:47 0.165 5000 OTO
14:47:47 0.165 600 OTO
14:47:33 0.165 3000 OTO
14:47:27 0.165 100 OTO
14:42:07 0.16 20 OTO
14:41:22 0.174 5000 OTO
14:41:19 0.174 5000 OTO
14:40:51 0.16 100 OTO
14:40:42 0.16 42400 OTO
14:40:40 0.161 5000 OTO
14:37:34 0.16 5000 OTO
14:37:31 0.16 15000 OTO
14:33:37 0.16 10000 OTO
14:27:44 0.15505 100 OTO
14:27:37 0.15901 100 OTO
14:08:27 0.158 37650 OTO
14:08:25 0.158 20000 OTO
13:31:44 0.158 5000 OTO
13:26:54 0.158 5000 OTO
13:26:51 0.158 5000 OTO
13:18:14 0.15 4552 OTO
13:17:13 0.15 5400 OTO
13:17:11 0.15 9600 OTO
13:16:46 0.15 10000 OTO
13:16:41 0.15 9477 OTO
13:16:13 0.15 710 OTO
13:16:03 0.15 45000 OTO
13:16:03 0.15 7790 OTO
13:15:57 0.15 6500 OTO
13:15:50 0.1505 5000 OTO
13:14:45 0.1515 5000 OTO
13:14:32 0.1515 14000 OTO
12:53:11 0.158 3220 OTO
12:50:10 0.155 5523 OTO
12:41:43 0.156 1000 OTO
12:27:28 0.158 20000 OTO
12:27:15 0.152 5000 OTO
12:23:58 0.1519 5000 OTO
12:22:20 0.152 3944 OTO
12:19:09 0.152 10000 OTO
12:16:50 0.152 7500 OTO
12:16:11 0.152 12556 OTO
12:16:11 0.152 7444 OTO
12:09:32 0.1555 2500 OTO
12:09:28 0.1555 7500 OTO
12:06:39 0.155 6000 OTO
12:06:32 0.16 860 OTO
12:03:47 0.16 1000 OTO
12:03:37 0.155 900 OTO
12:03:24 0.155 100 OTO
11:58:50 0.16 612 OTO
11:58:39 0.16 2500 OTO
11:57:05 0.155 8000 OTO
11:56:21 0.155 7000 OTO
11:50:54 0.157 10000 OTO
11:49:16 0.16 10000 OTO
11:48:46 0.158 5000 OTO
11:48:35 0.158 5000 OTO
11:46:43 0.1572 575 OTO
11:46:10 0.16 400 OTO
11:45:50 0.16 100 OTO
11:43:13 0.16 600 OTO
11:42:58 0.1623 50 OTO
11:42:52 0.16 14600 OTO
11:42:52 0.16 400 OTO
11:42:38 0.16 6000 OTO
11:42:19 0.16 6000 OTO
11:42:18 0.1575 3800 OTO
11:35:07 0.16 3000 OTO
11:25:25 0.155 1200 OTO
11:22:44 0.1505 220 OTO
11:21:41 0.16 10000 OTO
11:21:08 0.1572 1250 OTO
11:19:15 0.16 50 OTO
11:18:54 0.16 100 OTO
11:14:20 0.155 20000 OTO
11:10:48 0.16 2500 OTO
11:10:33 0.155 20000 OTO
11:10:15 0.155 10000 OTO
11:10:09 0.155 25000 OTO
11:07:28 0.1505 975 OTO
11:06:36 0.1505 500 OTO
11:06:22 0.16 20000 OTO
11:05:13 0.16 8000 OTO
11:05:08 0.168 12000 OTO
11:04:28 0.169 5000 OTO
11:04:25 0.169 23000 OTO
11:04:19 0.159 7000 OTO
11:04:18 0.154 10000 OTO
11:03:43 0.156 5000 OTO
11:02:31 0.154 7500 OTO
11:00:28 0.154 10000 OTO
10:58:46 0.154 150 OTO
10:56:04 0.1485 5000 OTO
10:55:23 0.149 10310 OTO
10:55:12 0.149 31000 OTO
10:54:54 0.149 5000 OTO
10:54:52 0.15 5000 OTO
10:54:43 0.149 5000 OTO
10:54:38 0.15 5000 OTO
10:54:25 0.15 19500 OTO
10:53:58 0.149 30000 OTO
10:53:22 0.149 10000 OTO
10:52:46 0.149 21100 OTO
10:52:08 0.144 500 OTO
10:51:06 0.149 2000 OTO
10:48:58 0.149 1900 OTO
10:44:12 0.154 10000 OTO
10:44:05 0.15 20000 OTO
10:43:49 0.149 5000 OTO
10:43:34 0.148 5000 OTO
10:40:26 0.148 4700 OTO
10:35:57 0.148 900 OTO
10:34:41 0.1474 5000 OTO
10:33:36 0.149 10000 OTO
10:31:20 0.1455 3068 OTO
10:31:20 0.154 1932 OTO
10:31:20 0.15 1932 OTO
10:31:17 0.154 5000 OTO
10:31:12 0.154 5000 OTO
10:31:00 0.154 5000 OTO
10:30:11 0.154 1000 OTO
10:23:12 0.147 2817 OTO
10:12:59 0.14 10583 OTO
10:12:49 0.14 1984 OTO
10:12:41 0.138 5000 OTO
10:12:13 0.138 290 OTO
10:10:08 0.138 4710 OTO
10:09:05 0.1364 1450 OTO
10:03:58 0.1362 1450 OTO
09:58:10 0.138 5900 OTO
09:57:57 0.138 100 OTO
09:40:05 0.13 20000 OTO
09:39:43 0.13 4000 OTO
09:38:49 0.13 10000 OTO
09:35:08 0.13 8590 OTO
09:33:55 0.13 3100 OTO
09:33:27 0.128 10356 OTO
09:33:17 0.128 3044 OTO .. @ bid (mine) set pre mkt
09:30:49 0.13 14800 OTO
09:30:40 0.1304 100 OTO
09:30:06 0.128 47 OTO .. 47 + 53 + 100
09:30:01 0.12955 53 OTO .. 53 + 47 + 100
since K was filed on 9.11.18 ..
November 1, 2018
INNOVATION PHARMACEUTICALS EXPANDS BRILACIDIN PATENT PORTFOLIO
October 24, 2018
INNOVATION PHARMACEUTICALS GRANTED END-OF-PHASE 2 MEETING
October 22, 2018
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON KEVETRIN PROGRAM; BRIDGING TOXICOLOGY EFFORTS AIMED AT DEVELOPING AN ORAL P53 ANTI-CANCER DRUG CANDIDATE
October 12, 2018
INNOVATION PHARMACEUTICALS BRILACIDIN AS A NOVEL INHIBITOR OF PHOSPHODIESTERASE 4 (PDE4) SUPPORTS ITS POTENTIAL TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES
October 9, 2018
INNOVATION PHARMACEUTICALS SECURES UP TO $10 MILLION IN ADDITIONAL FINANCING TO ADVANCE CLINICAL PIPELINE
September 24, 2018
INNOVATION PHARMACEUTICALS PROVIDES A COMPARATIVE PERSPECTIVE ON BRILACIDIN’S POTENTIAL TO UNLOCK THE ORAL MUCOSITIS MARKET: PHARMA INDUSTRY ATTACKS SEVERE PAIN AND SUFFERING DUE TO CANCER TREATMENTS
September 20, 2018
INNOVATION PHARMACEUTICALS PROVIDES CORPORATE UPDATE HIGHLIGHTING UPCOMING MILESTONES AND EVENTS
http://www.ipharminc.com/press-release/
Form Type Description Filing Date
8-K Current report, item 7.01 2018-10-24
4 Statement of changes in beneficial ownership ... 2018-10-16
4 Statement of changes in beneficial ownership ... 2018-10-15
8-K Current report, item 7.01 2018-10-10
8-K Current report, items 1.01, 5.03, 7.01, and 9... 2018-10-09
424B5 Prospectus 2018-10-09
4 Statement of changes in beneficial ownership ... 2018-09-24
4 Statement of changes in beneficial ownership ... 2018-09-24
8-K Current report, item 5.02 2018-09-21
10-K Annual report 2018-09-11
http://www.ipharminc.com/financials/
a good weekend to all Innovation Pharma Investors ..
4kids
(2)
(0)